SA Transcripts • Nov. 13, 2014
Sep. 25, 2013, 7:35 AM
- Oncothyreon (ONTY) surges 29% after saying that Merck KGa (MKGAF.PK) intends to carry out a Phase III trial of Oncothyreon's tecemotide immunotherapy in patients with advanced non-small cell lung cancer.
- While tecemotide failed to meet the primary goal of a previous trial of improving survival in the overall patient population, the drug did achieve survival times 30.8 months vs 20.6 months for a placebo in a sub-group. (PR)
Dec. 19, 2012, 8:39 AMStimuvax, a lung cancer vaccine that Germany's Merck (MKGAF.PK) has licensed from Oncothyreon (ONTY), failed to improve overall survival in a Phase III study. However, "notable treatment effects were observed in certain subgroups of patients." That's not enough to convince analysts: "Despite potential positive effects in subgroups, we consider the drug dead," says Deutsche Bank. Oncothyreon collapses 61%, while Merck is -2.9% in Frankfurt. (PR) | Comment!
Oct. 16, 2012, 9:01 AM
Nov. 18, 2011, 3:55 PMADRs of German chemical and pharmaceutical maker Merck KGaA (MKGAY.PK +0.7%) get a lift after receiving a positive opinion from a committee of the European Medicines Agency for its application to extend the indication of Rebif, its leading treatment for relapsing forms of multiple sclerosis. | Comment!
There are no StockTalks on this stock yet.
MKGAY vs. ETF Alternatives
Merck KGaA is a global pharmaceutical, chemical and life science company with a history that began in 1668 and a future shaped by approximately 40,000 employees in 67 countries. Merck KGaA's subsidiaries in North America operate using the umbrella brand "EMD".
Other News & PR